Stock
Ownership of a fraction of a corporation and the right to claim a share of the corporation's assets and profits equal to the amount of stock owned
US listed securityListed on NASDAQ
IE headquarteredHeadquartered in Dublin, Leinster, Ireland
addFollow
Amarin Corporation plc
$7.55
AMRN
Jan 25, 3:42:20 PM GMT-5 · USD · NASDAQ · Disclaimer
In the news
Financial performance
| (USD) | Q3 2020 | Year/year change |
|---|---|---|
Revenue | 156.50M | arrow_upward39.22% |
Net income | -6.79M | arrow_downward-96.07% |
| Diluted EPS | -0.02 | arrow_downward-100.00% |
| Net profit margin | -4.34% | arrow_downward-40.91% |
| Operating income | -6.94M | arrow_downward-53.61% |
| Net change in cash | -6.80M | arrow_downward-101.50% |
| Cash on hand | 207.21M | arrow_downward-69.22% |
| Cost of revenue | 33.07M | arrow_upward29.98% |
About
Amarin Corporation is a biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza. Wikipedia
CEO
Founded
1993
Website
Employees
965
Key stats
Previous close
The last closing price
$6.55
Day range
The difference between the high and low prices over the past day
$6.96 - $7.64
Year range
The difference between the high and low prices over the past 52 weeks
$3.36 - $20.80
Market cap
A valuation method that multiplies the price of a company's stock by the total number of outstanding shares.
2.95B USD
Volume
The average number of shares traded each day over the past 30 days
8.02M
P/E ratio
The ratio of current share price to trailing twelve month EPS that signals if the price is high or low compared to other stocks
-
Dividend yield
The ratio of annual dividend to current share price that estimates the dividend return of a stock
-
About
Amarin Corporation is a biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza. Wikipedia
CEO
Founded
1993
Website
Employees
965
